Liso-cel

Phase 1Biologic

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Liso-cel is one of 8 biologic programs targeting DLBCL - Diffuse Large B Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DLBCL - Diffuse Large B Cell LymphomaActive, not recruiting

DLBCL - Diffuse Large B Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in DLBCL - Diffuse Large B Cell Lymphoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

1 2

Eloxatin

Teva

Phase 3

1 3

Jaypirca

Eli Lilly

Phase 2

2 4

Dexametasone

UUniversity of Malaya

Phase 3

1 5

R-CHOP

IIncyte Biosciences Japan GK

Phase 2

1 6

POLA-R-CHP

FFudan University

Phase 2

1 7

R-Minichop

UUniversität des Saarlandes

Phase 2

1 8

Liso-cel

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

DLBCL - Diffuse Large B Cell Lymphoma

NCT05621096

Q4 2028

Phase 2Recruiting

Lymphoma

NCT07015242

Clinical

Trials by Indication[1]

Active, not recruiting·UUniversity of Nebraska·Phase 1·NCT05621096·33 enrolled

Lymphoma1 trial

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015242·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Liso-cel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liso-cel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liso-cel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Liso-cel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Follicular Lymphoma1 trial

Chronic Lymphocytic Leukemia1 trial

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News